MAP2K1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR::ABL1 protein constitutively activates, Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phosphoinositide 3‐kinase (PI3K)/Akt, and mitogen‐activated protein kinase kinase 1/2 (MEK1/2)/extracellular signal‐regulated kinase 1/2 (ERK1/2) pathways, which are involved in CML cell proliferation and survival.2